- Home
- ANSC vs URGN Comparison
ANSC vs URGN Comparison
Compare ANSC & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANSC
- URGN
- Stock Information
- Founded
- ANSC 2021
- URGN 2004
- Country
- ANSC United States
- URGN United States
- Employees
- ANSC N/A
- URGN N/A
- Industry
- ANSC
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- ANSC
- URGN Health Care
- Exchange
- ANSC Nasdaq
- URGN Nasdaq
- Market Cap
- ANSC 458.0M
- URGN 465.9M
- IPO Year
- ANSC 2023
- URGN 2017
- Fundamental
- Price
- ANSC $10.65
- URGN $10.63
- Analyst Decision
- ANSC
- URGN Strong Buy
- Analyst Count
- ANSC 0
- URGN 6
- Target Price
- ANSC N/A
- URGN $40.75
- AVG Volume (30 Days)
- ANSC 37.7K
- URGN 419.1K
- Earning Date
- ANSC 01-01-0001
- URGN 03-10-2025
- Dividend Yield
- ANSC N/A
- URGN N/A
- EPS Growth
- ANSC 84.41
- URGN N/A
- EPS
- ANSC 0.19
- URGN N/A
- Revenue
- ANSC N/A
- URGN $90,398,000.00
- Revenue This Year
- ANSC N/A
- URGN $43.60
- Revenue Next Year
- ANSC N/A
- URGN $103.77
- P/E Ratio
- ANSC $55.01
- URGN N/A
- Revenue Growth
- ANSC N/A
- URGN 9.29
- 52 Week Low
- ANSC $10.16
- URGN $9.03
- 52 Week High
- ANSC $10.67
- URGN $20.70
- Technical
- Relative Strength Index (RSI)
- ANSC 62.73
- URGN 44.41
- Support Level
- ANSC $10.62
- URGN $11.12
- Resistance Level
- ANSC $10.67
- URGN $11.91
- Average True Range (ATR)
- ANSC 0.03
- URGN 0.56
- MACD
- ANSC -0.00
- URGN -0.07
- Stochastic Oscillator
- ANSC 80.00
- URGN 3.87
About ANSC Agriculture & Natural Solutions Acquisition Corporation
Agriculture & Natural Solutions Acquisition Corp is a blank check company.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.